In the third quarter, Synergy had good news of prescriptions increasing 105 percent since the second quarter financial results. In the beginning of February the company announced it received enough cash balance to access additional capital. The company has one commercial product available Trulance for chronic idiopathic constipation and irritable bowel syndrome with constipation. This company is focused gastrointestinal tract diseases, Synergy, is proud to retain all their own profits by partnering with any companies to develop, discover or commercialize their products. Market cap: $456.66 million current stock price: $2.03Ĭlosing out our micro-cap stocks on the NASDAQ list is Synergy Pharmaceuticals. Though the company did have a minor decrease of 3.35 percent in their stock price over the last month, it didn’t push back their stock price too much over increasing 10.58 percent in the last three months to $6.06.
Investing in micro cap stocks full#
With a full enrolment for a Phase 3 clinical study (PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer) announced early 2018, this could be a very promising year for Progenics. The drug is meant to help patients with specific neuroendocrine tumours. At the end of 2017, the company announced a US Food and Drug Administration (FDA) acceptance for its new drug application (NDA) for Azedra. Progenics has a multitude of cancer targeted products and therapies in different oncology departments. Market cap: $425.83 million current stock price: $6.06 Progenics Pharmaceuticals (NASDAQ: PGNX ) The next year should be an interesting one for MannKind if it decide to bring new and/or significantly develop new products on its pipeline. MannKind’s share price has increased 16.22 percent in the last month an only dropped 8.71 percent in the last three months. “David is a world renowned diabetes expert and represents an important addition to our executive leadership team,” the press release stated. The company recently welcomed a new chief medical officer which may have been why their stock price improved over the last month-more than any other company mentioned in this article. Next is Mannkind, who has a single product consisting of an Insulin inhaler called Afrezza.
Market cap: $332.42 million current stock price: $2.89 It will be interesting to see where 2018 takes Idera and Biocryst with their merger.
Over a one month period, shares of Idera have decreased 23.73 percent but increased 12.43 percent in the last six months. The company announced a merger with Biocryst (NASDAQ: BCRX ) in late January to team up and develop products for rare diseases, which makes them a company to watch moving forward. The company has teamed up with Vivelix pharmaceuticals and GlaxoSmithKline (NYSE: GSK ) to help develop and commercialize a product again autoimmune diseases and renal diseases, respectively. Through two technology platforms, Idera is developing nucleic acids into treatments to fight certain cancers and rare diseases. Market cap: $378.05 million current stock price: $1.94 While Casi’s share price has decreased 8.07 percent in the last month to $3.76, but it did have an impressive gain of 37.73 percent in the last three months. Its product ENMD-2076 for breast cancer and a rare type of breast cancer is going into a Phase 3 clinical study and could be the next product on the market by Casi. It has a large focus of their products as generic alternatives-25 to be exact, with more applications pending.
The company is looking to have a greater presence in the Chinese pharmaceutical market through partnerships, commercialization and development.
Market cap: $244.65 million current stock price: $3.76įirst on our list is Casi Pharmaceuticals. Top Battery Metals Stocks on the TSX and TSXV.
0 kommentar(er)
